Lilly’s Neutralizing Antibodies Reduce Risk Of Serious COVID-19 Outcomes By 70%
Executive Summary
The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.
You may also be interested in...
Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism
After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.
EMA Reviewing Two MAb Combinations For COVID-19
The European Medicines Agency's special review process that was used to help EU member states issue emergency use approvals for dexamethasone in COVID-19 patients is now being applied to two antibody combinations from Regeneron/Roche and Lilly.
Big COVID-19-Related Sales Drive Lilly’s Strong Q4 Performance
Neutralizing antibody bamlanivimab brought in $871m during the fourth quarter, skewing already solid growth upwards. Discussion of donanemab in Alzheimer’s dominated Lilly’s quarterly call.